5.45
0.55%
-0.03
Syros Pharmaceuticals Inc. 주식(SYRS)의 최신 뉴스
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) to Post FY2025 Earnings of ($0.77) Per Share, Brookline Capital ... - MarketBeat
MarketBeat
Syros Pharmaceuticals, Inc. Forecasted to Post FY2026 Earnings of $1.62 Per Share (NASDAQ:SYRS) - MarketBeat
MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Earns "Buy" Rating from HC Wainwright - MarketBeat
MarketBeat
Syros Pharmaceuticals (NASDAQ:SYRS) Announces Earnings Results - MarketBeat
MarketBeat
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic Developments and ... - GuruFocus.com
GuruFocus.com
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q1 2024 Earnings Call Transcript - Insider Monkey
Insider Monkey
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Business Wire
Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies UK
Yahoo Movies UK
Short Interest in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Decreases By 22.0% - MarketBeat
MarketBeat
Syros Pharmaceuticals (SYRS) Set to Announce Earnings on Tuesday - Defense World
Defense World
Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
MarketBeat
ImmunityBio (IBRX) Stock Jumps 43.2%: Will It Continue to Soar? - Yahoo Singapore News
Yahoo Singapore News
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
Syros Pharmaceuticals (SYRS) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
MarketBeat
Syros to Participate in Upcoming Investor Conferences - Business Wire
Business Wire
What Did Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) CEO Take Home Last Year? - Yahoo New Zealand News
Yahoo New Zealand News
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Strength Seen in Syros Pharmaceuticals, Inc. (SYRS): Can Its 5.4% Jump Turn into More Strength? - Yahoo Lifestyle UK
Yahoo Lifestyle UK
Will Femasys Inc. (FEMY) Report Negative Q1 Earnings? What You Should Know
Zacks Investment Research
Syros Pharmaceuticals (NASDAQ:SYRS) Stock Crosses Below 50-Day Moving Average of $5.94 - MarketBeat
MarketBeat
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for - Zacks Investment Research
Zacks Investment Research
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
Analysts Estimate Syros Pharmaceuticals, Inc. (SYRS) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Yahoo Finance
Syros Pharmaceuticals (NASDAQ:SYRS) Shares Pass Below 50 Day Moving Average of $6.38 - MarketBeat
MarketBeat
Cyclin Dependent Kinase 7 Market Analysis | Beta Pharma Inc, Cyclacel Pharmaceuticals Inc, Qurient Co Ltd, Syros ... - Currency News Centre
Currency News Centre
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros Pharmaceuticals
Zacks Investment Research
The Zacks Analyst Blog Highlights Bristol Myers, Moderna, 2seventy bio, Amylyx Pharmaceuticals and Syros ... - Yahoo Finance
Yahoo Finance
Biotech Stock Roundup: MRNA Up on Vaccine Data, BMY's Updates & More News
Zacks Investment Research
Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML
Zacks Investment Research
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?
Zacks Investment Research
Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock? - Yahoo Finance Australia
Yahoo Finance Australia
Crude Oil Down Over 1%; Cognyte Software Shares Plummet
Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit ... - Business Wire
Business Wire
Top 3 Health Care Stocks You'll Regret Missing This Month
Benzinga
Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON - Benzinga
Benzinga
Syros Pharmaceuticals Full Year 2023 Earnings: Misses Expectations - Yahoo Finance
Yahoo Finance
Syros enrols subjects in myelodysplastic syndrome drug trial - Clinical Trials Arena
Clinical Trials Arena
SYRS Stock Quote Price and Forecast - CNN
CNN
Painful week for private equity firms invested in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) after 11% drop, institutions also suffered losses - Simply Wall St
Simply Wall St
Syros to Participate in TD Cowen 44th Annual Health Care Conference - Business Wire
Business Wire
Long Term Trading Analysis for (SYRS) - Stock Traders Daily
Stock Traders Daily
Thinking about buying stock in Biofrontera, Snowflake, Syros Pharmaceuticals, Agenus, or Kopin? - Marketscreener.com
Marketscreener.com
Thinking about buying stock in Rivian Automotive, Bitdeer Technologies, Syros Pharmaceuticals, Lucid Group, or Ayr ... - Marketscreener.com
Marketscreener.com
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why
Zacks Investment Research
Syros (SYRS) Stock Surges 200% in 3 Months: Here's Why - Nasdaq
Nasdaq
Are You Looking for a Top Momentum Pick? Why Syros Pharmaceuticals, Inc. (SYRS) is a Great Choice
Zacks Investment Research
Syros Pharmaceuticals, Inc. (SYRS) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance
Yahoo Finance
What Makes Syros Pharmaceuticals, Inc. (SYRS) a New Buy Stock
Zacks Investment Research
자본화:
|
볼륨(24시간):